Market Overview:
The global bio similars/subsequent entry biologic market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biosimilars, and technological advancements in the field of biologics. The monoclonal antibodies segment is expected to account for the largest share of the global bio similars/subsequent entry biologic market in 2018. This segment is also projected to grow at a CAGR of 10.9% during the forecast period from 2018 to 2030. The erythropoietin segment is expected to grow at the highest CAGR during this period owing to its increasing use in anemia treatment therapies. In terms of application, tumor accounted for the largest share of the global bio similars/subsequent entry biologic market in 2017 and this trend is projected continue duringthe forecast period from2018to2030 .
Product Definition:
Bio Similars are drugs that are created to be similar to an already existing drug. The purpose of Bio Similars is to create a cheaper, more accessible alternative to the original drug.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules that are produced by the body's immune system in response to a specific injury or infection. The specificity of the MAB can be to an object (e.g., antigen), location, or type of cell/organism causing the damage. There are two types of MABs: ones that bind directly to an injured site and those that attach themselves to any nearby antigen (i.e., they can be attached either temporarily or permanently).
Interferon:
Interferons are a class of pharmaceutical drugs that are used to treat several types of cancer and viral diseases. Interferon is an immunomodulating drug that works by enhancing the immune response to viruses, bacteria, and malignant cells.
Application Insights:
The tumor application segment dominated the global subsequent entry biologics market in 2017, accounting for over 40% of the overall revenue share. The growing incidences of cancer are expected to be a major factor driving this segment. According to WHO, it is estimated that over 1 in 6 people across the globe will develop cancer during their lifetime and around 1 death due to cancer occurs every 3 seconds globally.
Moreover, according to data published by NCBI, it is projected that around 2 million people die from malignant tumors each year and around 14 million individuals are diagnosed with these diseases worldwide. Increasing R&D activities pertaining towards development of subsequent entry biologics for treatment purposes is anticipated to fuel market growth during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to high R&D investments and increasing focus on product approvals. In addition, rising incidences of cancer and other chronic diseases are also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the next eight years owing to untapped opportunities in this region. There are a large number of patients suffering from chronic diseases such as cancer, diabetes, cardiovascular disorders, etc., which need treatment with subsequent entry biologics/biosimilars for effective management of their disease symptoms but do not have access due to affordability issues or because they reside in regions without approved biosimilar/biosimilar products. This scenario presents an opportunity for manufacturers who can provide affordable treatment options for these patients by introducing subsequent entry drugs into the Asian market (excluding Japan).
Growth Factors:
- Increasing demand for Bio Similars/Subsequent Entry Biologics due to their efficacy and safety as compared to the traditional drugs.
- Rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders which requires long-term treatment with Bio Similars/Subsequent Entry Biologics.
- Technological advancements in the field of biotechnology that are helping in the development of novel therapeutics such as Bio Similars/Subsequent Entry Biologics.
- Growing number of clinical studies supporting the use of Bio Similars/Subsequent Entry Biologics for various indications thereby increasing their adoption rates worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Bio Similars/Subsequent Entry Biologic Market Research Report
By Type
Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other
By Application
Tumor, Diabetes, Cardiovascular, Hemophilia, Other
By Companies
Sun Pharma, Synthon Pharmaceuticals, Teva Pharmaceutical Industries, LG Life Sciences, Celltrion Biocon, Hospira, Merck, Biogen idec, Genentech (Roche), Pfizer, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG, AbbVie, Sanofi-Aventis, Johnson & Johnson, Novo Nordisk, Eli Lilly, Novartis, 3sbio, Biotech, Gelgen, Innovent, Dong Bao, Ganlee
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Bio Similars/Subsequent Entry Biologic Market Report Segments:
The global Bio Similars/Subsequent Entry Biologic market is segmented on the basis of:
Types
Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tumor, Diabetes, Cardiovascular, Hemophilia, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sun Pharma
- Synthon Pharmaceuticals
- Teva Pharmaceutical Industries
- LG Life Sciences
- Celltrion Biocon
- Hospira
- Merck
- Biogen idec
- Genentech (Roche)
- Pfizer
- Celltrion
- Biocon
- Amgen
- Samsung Biologics
- Mylan
- Dr. Reddy's Laboratories
- Stada Arzneimittel AG
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Novo Nordisk
- Eli Lilly
- Novartis
- 3sbio
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
Highlights of The Bio Similars/Subsequent Entry Biologic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Other
- By Application:
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bio Similars/Subsequent Entry Biologic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bio-similar is a term used in the pharmaceutical industry to describe drugs that are structurally or functionally similar to other drugs already on the market. This allows for more efficient and effective drug development by allowing companies to study how a particular drug affects human cells and tissues in vitro, before attempting to develop it into a new medication. Subsequent entry biologic refers to any biotech company that develops therapeutics based on novel mechanisms of action after first identifying an existing therapy with similar efficacy or safety profiles.
Some of the major companies in the bio similars/subsequent entry biologic market are Sun Pharma, Synthon Pharmaceuticals, Teva Pharmaceutical Industries, LG Life Sciences, Celltrion Biocon, Hospira, Merck, Biogen idec, Genentech (Roche), Pfizer, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG, AbbVie, Sanofi-Aventis, Johnson & Johnson, Novo Nordisk, Eli Lilly, Novartis, 3sbio, Biotech, Gelgen, Innovent, Dong Bao, Ganlee.
The bio similars/subsequent entry biologic market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bio Similars/Subsequent Entry Biologic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bio Similars/Subsequent Entry Biologic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bio Similars/Subsequent Entry Biologic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bio Similars/Subsequent Entry Biologic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bio Similars/Subsequent Entry Biologic Market Size & Forecast, 2018-2028
4.5.1 Bio Similars/Subsequent Entry Biologic Market Size and Y-o-Y Growth
4.5.2 Bio Similars/Subsequent Entry Biologic Market Absolute $ Opportunity
Chapter 5 Global Bio Similars/Subsequent Entry Biologic Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bio Similars/Subsequent Entry Biologic Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Interferon
5.2.3 Erythropoietin
5.2.4 Insulin
5.2.5 Vaccines
5.2.6 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bio Similars/Subsequent Entry Biologic Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bio Similars/Subsequent Entry Biologic Market Size Forecast by Applications
6.2.1 Tumor
6.2.2 Diabetes
6.2.3 Cardiovascular
6.2.4 Hemophilia
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bio Similars/Subsequent Entry Biologic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bio Similars/Subsequent Entry Biologic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bio Similars/Subsequent Entry Biologic Analysis and Forecast
9.1 Introduction
9.2 North America Bio Similars/Subsequent Entry Biologic Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bio Similars/Subsequent Entry Biologic Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Interferon
9.6.3 Erythropoietin
9.6.4 Insulin
9.6.5 Vaccines
9.6.6 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bio Similars/Subsequent Entry Biologic Market Size Forecast by Applications
9.10.1 Tumor
9.10.2 Diabetes
9.10.3 Cardiovascular
9.10.4 Hemophilia
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bio Similars/Subsequent Entry Biologic Analysis and Forecast
10.1 Introduction
10.2 Europe Bio Similars/Subsequent Entry Biologic Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bio Similars/Subsequent Entry Biologic Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Interferon
10.6.3 Erythropoietin
10.6.4 Insulin
10.6.5 Vaccines
10.6.6 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bio Similars/Subsequent Entry Biologic Market Size Forecast by Applications
10.10.1 Tumor
10.10.2 Diabetes
10.10.3 Cardiovascular
10.10.4 Hemophilia
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bio Similars/Subsequent Entry Biologic Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bio Similars/Subsequent Entry Biologic Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bio Similars/Subsequent Entry Biologic Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Interferon
11.6.3 Erythropoietin
11.6.4 Insulin
11.6.5 Vaccines
11.6.6 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bio Similars/Subsequent Entry Biologic Market Size Forecast by Applications
11.10.1 Tumor
11.10.2 Diabetes
11.10.3 Cardiovascular
11.10.4 Hemophilia
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bio Similars/Subsequent Entry Biologic Analysis and Forecast
12.1 Introduction
12.2 Latin America Bio Similars/Subsequent Entry Biologic Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bio Similars/Subsequent Entry Biologic Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Interferon
12.6.3 Erythropoietin
12.6.4 Insulin
12.6.5 Vaccines
12.6.6 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bio Similars/Subsequent Entry Biologic Market Size Forecast by Applications
12.10.1 Tumor
12.10.2 Diabetes
12.10.3 Cardiovascular
12.10.4 Hemophilia
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bio Similars/Subsequent Entry Biologic Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bio Similars/Subsequent Entry Biologic Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bio Similars/Subsequent Entry Biologic Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Interferon
13.6.3 Erythropoietin
13.6.4 Insulin
13.6.5 Vaccines
13.6.6 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bio Similars/Subsequent Entry Biologic Market Size Forecast by Applications
13.10.1 Tumor
13.10.2 Diabetes
13.10.3 Cardiovascular
13.10.4 Hemophilia
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bio Similars/Subsequent Entry Biologic Market: Competitive Dashboard
14.2 Global Bio Similars/Subsequent Entry Biologic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sun Pharma
14.3.2 Synthon Pharmaceuticals
14.3.3 Teva Pharmaceutical Industries
14.3.4 LG Life Sciences
14.3.5 Celltrion Biocon
14.3.6 Hospira
14.3.7 Merck
14.3.8 Biogen idec
14.3.9 Genentech (Roche)
14.3.10 Pfizer
14.3.11 Celltrion
14.3.12 Biocon
14.3.13 Amgen
14.3.14 Samsung Biologics
14.3.15 Mylan
14.3.16 Dr. Reddy's Laboratories
14.3.17 Stada Arzneimittel AG
14.3.18 AbbVie
14.3.19 Sanofi-Aventis
14.3.20 Johnson & Johnson
14.3.21 Novo Nordisk
14.3.22 Eli Lilly
14.3.23 Novartis
14.3.24 3sbio
14.3.25 Biotech
14.3.26 Gelgen
14.3.27 Innovent
14.3.28 Dong Bao
14.3.29 Ganlee
